Stay updated with breaking news from Stephan Jackman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating) CEO Stephan Jackman purchased 37,000 shares of the business’s stock in a transaction on Friday, April 28th. The stock was purchased at an average cost of $0.54 per share, with a total value of $19,980.00. Following the completion of the acquisition, the chief executive officer now owns 45,500 […]
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer's disease (Alzheimer's). In addition to having conducted Alzamend's
Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.According to an Alzamend release, the study will examine safety, efficacy and tolerability of multiple ascending doses of ALZN002 compared with placebo in 20 to 30 individuals with mild to moderate
The U.S. biotech Alzamend Neuro has launched a phase 1/2a trial of a therapeutic vaccine for Alzheimer’s disease based on a patient’s immune dendritic cells.
Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder, major depressive... | April 3, 2023